Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.423 | Association between experiential avoidance and long-term hypnotic medication use among psychiatric outpatients | Dr Li Cheuk Wing |
| 2010.295 | A prospective audit of LMA use and its laryngoharyngeal adverse event in a university-based hospital | Dr. Li Cheuk Yin |
| 2012.477 | Promotion of cord blood stem cell homing/engraftment by enhancing the expression of a novel tetraspanin protein CD9 | Dr. LI Chi Kong |
| 2012.448 | Role and reguatory signals of novel genes RGS1 and RGS13 in the homing and engraftment of human hematopoietic stem/progenitor cells for bone marrow immunologic reconstitution | Dr. LI Chi Kong |
| 2010.106 | International Study of chronic myelod leukaemia (CML) Treatment and Outcomes in Children and Adolescents | Dr. LI CHI KONG |
| 2013.307 | Preclinical evaluation of CD9 as a target for treatment of pediatric B-cell acute lymphoblastic leukemia via modulations of migration and engraftment activities | Dr. LI Chi Kong |
| 2009.330 | A cross-sectional, multi-center, epidemiological study in Western and Asian countries in children and adolescents with Chronic Hepatitis B | Dr. Li Chi Kong |
| 2008.423 | Pilot Study of Efficacy and Safety of Chinese Herbal Medicine Gualou (Fructus Trichosanthis) in Treating Beta-thalassaemia Intermedia Patients | Prof Li Chi Kong |
| 2007.361 | An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | Dr. LI Chi Kong |
| 2013.482 | Oral Arsenic trioxide in Management of Newly Diagnosed and Relapsed or refractory Acute Promyelocytic Leukemia (PML/RARα) in Children | Dr. LI Chi Kong |
| 2013.047 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. LI Chi Kong |
| 2010.064 | A Prospective, Open-label, Non-comparative Study to Assess the Safety, Tolerability and Efficacy of Voriconazole for the Primary and Salvage Treatment of Invasive Candidiasis, Candidemia, and Esophageal Candidiasis in Pediatric subjects | Dr. LI CHI KONG |
| 2011.607 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B | Dr. Li Chi Kong |
| 2011.606 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A | Dr. Li Chi Kong |
| 2005.401 | International Collaborative Treatment Protocol for Infants Under One Year with Acute Lymphoblastic or Biphenotypic Leukemia | Dr. LI Chi Kong |
| 2008.077 | A Multi-center Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008 | Dr. Li Chi Kong |
| 2019.519 | A single arm, open-labelled Phase II clinical trial of anti-CD19 chimeric antigen receptor modified T-cell (CAR-T) for treatment of B-cell haematological malignancies |
Prof. LI Chi Kong 李志光教授 |
| 2020.445 | A Phase II CCCG-ALL Multi-center Trial of Dasatinib in Combination with Intensive Induction Therapy for Children with First Relapsed T-cell Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2020.404 | Driving Therapeutic Progress of Childhood Leukemia through Advanced Translational Research with Immediate and Long-term Impact |
Prof. LI Chi Kong 李志光教授 |
| 2019.704 | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
Prof. LI Chi Kong 李志光教授 |
| 2019.712 | The Prognostic factors of paediatric osteosarcoma in Hong Kong |
Prof. LI Chi Kong 李志光 |
| 2019.173 | Life Functioning and Quality of Life in Adult Survivors of Childhood Cancer |
Prof. LI Chi Kong 李志光 |
| 2020.035 | Evaluation of health-related quality of life and social support among caregivers of paediatric palliative care: A longitudinal prospective study |
Prof. LI Chi Kong 李志光 |
| 2019.297 | Retrospective review of bone health in transfusion dependent thalassemia patients in Hong Kong |
Prof. LI Chi Kong 李志光教授 |
| 2017.606 | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients |
Prof. LI Chi Kong 李志光 |
| 2019.107 | Prevalence of Iron deficiency and its impact on neurocognitive function in Hong Kong adolescent |
Prof. LI Chi Kong 李志光 |
| 2018.099 | Lifestyle modification program for treatment of nonalcoholic fatty liver disease in childhood cancer survivors |
Prof. LI Chi Kong 李志光 |
| 2019.091 | A retrospective study on compassionate use of Inotuzumab Ozogamicin in infants and younger children with relapsed or refractory acute lymphoblastic leukemia (ALL) |
Prof. LI Chi Kong 李志光 |
| 2017.607 | Chinese Children Cancer Group Relapsed ALL 2017 Study |
Prof. LI Chi Kong 李志光 |
| 2017.625 | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones: EsPhALL2017/COGAALL1631 |
Prof. LI Chi Kong 李志光 |
| 2019.023 | Neuroimaging, Cognitive and Life Functioning Outcomes in Patients with Hemophilia |
Prof. LI Chi Kong 李志光 |
| 2017.610 | To study the effect of Syk inhibition or deletion on terminal erythropoiesis of human thalassemic hematopoietic and stem progenitors |
Prof. LI Chi Kong 李志光教授 |
| 2018.303 | Registration in Center for International Blood and Marrow Transplant Research |
Prof. LI Chi Kong 李志光 |
| 2021.535 | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors | Prof. Li Chi Kong |
| 2020.540 | Chinese Children’s Cancer Group Acute Lymphoblastic Leukemia-2020 Project (CCCG-ALL-2020) |
Prof. LI Chi Kong 李志光 |
| 2021.280 | Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2021.110 | Effect of cancer treatment on testicular function and semen quality in male childhood and adolescent cancer survivors |
Prof LI Chi Kong 李志光 |
| 2021.314 | Effect of cancer treatment in adolescents and early adults on uterus and endometrial function |
Prof. LI Chi Kong 李志光 |
| 2025.388 | CCCG-ALL 2025 Intermediate- and high-risk B-cell acute lymphoblastic leukemia |
Prof. LI Chi Kong Chi Kong LI |
| 2025.657 | A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL |
Prof. LI Chi Kong 李志光教授 |
| 2025.659 | An Open Label Study Evaluating the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent β Thalassemia |
Prof. LI Chi Kong 李志光教授 |
| 2025.903 | An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia | Prof. LI Chi Kong |
| 2017.440 | The prevalence and clinical outcome of Ph-like Acute Lymphoblastic Leukaemia in a retrospective cohort |
Prof. LI Chi Kong 李志光 |
| 2016.643 | Genotyping variants determining mercaptopurine tolerance in Chinese children with Acute Lymphoblastic Leukaemia |
Prof. LI Chi Kong 李志光 |
| 2015.631 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. LI Chi Kong 李志光醫生 |
| 2014.364 | A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pediatric patients with severe hemophilia A | Dr. LI Chi Kong |
| 2016.247 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) |
Dr. LI Chi Kong 李志光 |
| 2016.406 | Genomic study on inherited bone marrow failure syndromes in Hong Kong by next generation sequencing |
Prof. LI Chi Kong 李志光 |
| 2017.355 | miRNA as diagnostic biomarkers for early detection of brain damage in acute leukaemia |
Prof. LI Chi Kong 李志光 |
| 2017.131 | Asparaginase activity and inhibitor in Chinese patients |
Prof. LI Chi Kong 李志光教授 |
Page 158 of 289.